Completed PHASE4 INTERVENTIONAL 2-arm NCT01930331

Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO

Safety, Tolerability, Pharmacokinetics and Efficacy, Phase Iv, Open Label Study of Fixed Arco® and Eurartesim® Therapies in Adults and Children With Uncomplicated P. Falciparum Malaria in Tanzania

Sponsor: Ifakara Health Institute

Conditions Malaria, Falciparum Plasmodium Falciparum

Interventions artemisinin/naphthoquine dihydroartemisinin/piperaquine phosphate

Updated 6 times since 2017 Last updated: Mar 13, 2018 Started: Jan 7, 2014 Primary completion: Jul 27, 2014 Completion: Jun 1, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01930331, this PHASE4 trial focuses on Malaria, Falciparum and Plasmodium Falciparum and remains completed. Sponsored by Ifakara Health Institute, it has been updated 6 times since 2014, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Mar 2018 — Jun 2018 [monthly]

Completed PHASE4

Status: Unknown Status → Completed

▶ Show 1 earlier version

Jan 2017 — Mar 2018 [monthly]

Unknown Status PHASE4

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ifakara Health Institute

Data source: Ifakara Health Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bagamoyo, Tanzania